Alpha-9 Oncology website screenshot

Alpha-9 Oncology

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company that spun out of the University of British Columbia and BC Cancer in 2019 to develop a portfolio of targeted cancer therapies. Alpha-9 engineers bespoke radiopharmaceutical molecules — optimizing the binder, linker, chelator, and radioisotope — to deliver radiation directly to tumor cells while limiting exposure to healthy tissue. The company operates purpose-built research facilities in Vancouver, BC and Boston, MA, and in October 2024 raised an oversubscribed $175M Series C led by Lightspeed Venture Partners and Ascenta Capital to advance its clinical pipeline. Alpha-9 is a drug developer and does not currently publish a public developer API; this profile captures its company identity and public-web surface for the API Evangelist network.

Alpha-9 Oncology is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Oncology, Radiopharmaceuticals, and Biotechnology.

Alpha-9 Oncology’s developer surface includes engineering blog, support, and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub
10.5/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyHealthcareOncologyRadiopharmaceuticalsBiotechnologyCancer TherapyClinical StageDrug Development

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 10.5/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 1.2 / 17
Access Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/alpha-9-oncology: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Alpha 9 Oncology Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 5

The organization behind the API

Website
Website
 Blog
Blog
 LinkedIn
LinkedIn
 Website
Website
 LinkedIn
LinkedIn

Source (apis.yml)

apis.yml Raw ↑ 
aid: alpha-9-oncology
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/alpha-9-oncology.png
name: Alpha-9 Oncology
description: Alpha-9 Oncology is a clinical-stage radiopharmaceutical company that spun out of the University of British Columbia
  and BC Cancer in 2019 to develop a portfolio of targeted cancer therapies. Alpha-9 engineers bespoke radiopharmaceutical
  molecules — optimizing the binder, linker, chelator, and radioisotope — to deliver radiation directly to tumor cells while
  limiting exposure to healthy tissue. The company operates purpose-built research facilities in Vancouver, BC and Boston,
  MA, and in October 2024 raised an oversubscribed $175M Series C led by Lightspeed Venture Partners and Ascenta Capital to
  advance its clinical pipeline. Alpha-9 is a drug developer and does not currently publish a public developer API; this profile
  captures its company identity and public-web surface for the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/alpha-9-oncology/refs/heads/main/apis.yml
x-type: company
x-source: general-catalyst-portfolio
x-tier: stub
x-tier-reason: portfolio-lead
x-api-surface: none
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Healthcare
- Oncology
- Radiopharmaceuticals
- Biotechnology
- Cancer Therapy
- Clinical Stage
- Drug Development
apis: []
common:
- type: DomainSecurity
  url: security/alpha-9-oncology-domain-security.yml
- type: Website
  url: https://www.a9oncology.com/
- type: Blog
  name: News & Events
  url: https://www.a9oncology.com/news/
- type: Support
  name: Contact
  url: https://www.a9oncology.com/contact/
- type: PrivacyPolicy
  url: https://www.a9oncology.com/privacy-policy/
- type: TermsOfService
  url: https://www.a9oncology.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/alpha9tx/
- type: Website
  url: https://a9oncology.com
- type: LinkedIn
  url: https://www.linkedin.com/company/alpha9tx
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence